Octapharma Plasma IncDecember 11, 2025

FDA 483 - Octapharma Plasma Inc - December 11, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Octapharma Plasma Inc

Record Details

An FDA inspection of Octapharma Plasma Inc. in Santa Fe Springs, CA, from December 8-11, 2025, identified a significant deficiency in the firm's standard operating procedures. The SOPs failed to include critical criteria for determining donor eligibility, specifically regarding accurate blood pressure measurement. This omission led to observed instances of noncompliance during donor screenings, potentially compromising the integrity of the donor screening process.

Company: Octapharma Plasma Inc
Inspection Date: December 11, 2025
Product Type: Biologics
Office: Los Angeles District Office
Person: Maurine Fadlalla (FDA_PERSONNEL)

Open in Dashboard

ID · 98d4c67b-9fa0-41ea-b834-f9bef9f8d3a0